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ABSTRACT OF DISSERTATION

MODIFICATION OF THE NUCLEOTIDE COFACTOR-BINDING SITE
OF CYTOCHROME P450 REDUCTASE TO ENHANCE
TURNOVER WITH NADH IN VIVO
NADPH-cytochrome P450 reductase is the electron transfer partner for the
cytochromes P450, heme oxygenase, and squalene monooxygenase, and is a
component of the nitric oxide synthases and methionine synthase reductase. P450
reductase shows very high selectivity for NADPH and uses NADH only poorly.
Substitution of tryptophan 677 with alanine (W677A) has been shown by others to yield
a 3-fold increase in turnover with NADH, but profound inhibition by NADP+ makes the
enzyme unsuitable for in vivo applications.

In the present study site-directed

mutagenesis of amino acids in the 2'-phosphate-binding site of the NADPH domain,
coupled with the W677A substitution, was used to generate a reductase that was able
to use NADH efficiently in vivo without inhibition by NADP+. Of 11 single, double, and
triple mutant proteins, two (R597M/W677A and R597M/K602W/W677A) showed up to a
500-fold increase in catalytic efficiency (kcat/Km) with NADH. Inhibition by NADP+ was
reduced by up to four orders of magnitude relative to the W677A protein and was equal
to or less than that of the wild-type reductase. Both proteins were 2- to 3-fold more
active than wild-type reductase with NADH in reconstitution assays with cytochrome
P450 1A2 and with squalene monooxygenase. In a recombinant cytochrome P450 2E1
Ames bacterial mutagenicity assay the R597M/W677A protein increased the sensitivity
to dimethylnitrosamine by approximately 2-fold, suggesting that the ability to use NADH

afforded a significant advantage in this in vivo assay. In addition to providing a valuable
tool for understanding the determinants of nucleotide cofactor specificity in this and
related enzymes, these mutants might also lend themselves to creation of
bioremediation schemes with increased enzymatic activity and robustness in situ, as
well as cost-effective reconstitution of enzyme systems in vitro that do not require the
use of expensive reducing equivalents from NADPH.
C. Lee Elmore
April 25, 2003
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CHAPTER ONE
INTRODUCTION

Cytochrome P450 Reductase, a Unique Flavoprotein
NADPH-cytochrome P450 reductase (EC 1.6.2.4) is the electron-donating
partner for the cytochromes P450, squalene monooxygenase, and heme oxygenase,
and is a component of the nitric oxide synthases and methionine synthase reductase.
P450 reductase is essential to cholesterol and steroid synthesis, and its importance is
underscored by the developmental abnormalities and embryonic lethality observed in
P450 reductase-null mice (Shen, O'Leary et al. 2002). P450 reductase contains one
mol of flavin adenine dinucleotide (FAD) and one mol of flavin mononucleotide (FMN)
per mol of enzyme. Reduced nicotinamide adenine dinucleotide phosphate (NADPH)
transfers two electrons as a hydride ion to the FAD of the enzyme, and FMN then
accepts single electrons from the FAD and acts as the exit point to the protein acceptor
such as the cytochromes P450.
Structure of Cytochrome P450 Reductase
P450 reductase is a multi-domain protein with the FAD and NADP(H) domains
homologous with ferredoxin-NADP+ reductase and the FMN domain homologous with
flavodoxin, suggesting that P450 reductase was formed from an ancestral gene fusion
event (Porter and Kasper 1986; Porter 1991). A fourth connecting domain acts as a
hinge to orient the two flavin-containing domains for electron transfer, and an NH2terminal membrane-binding domain anchors the protein to the cytosolic side of the
endoplasmic reticulum and the nuclear membrane. The three-dimensional structure
was determined by X-ray crystallography, and superbly illustrates the modular structure
of this unique flavoprotein (Wang, Roberts et al. 1997). Figure 1.1 illustrates, in cartoon
format, the multi-domain structure of the enzyme. The NADP(H) domain adopts the
typical dinucleotide fold structure consisting of alternating α–helices and β–strands, with
the nicotinamide cofactor binding in a cleft between the FAD and NADP(H) domains.
1

While the adenine portion of the dinucleotide cofactor was tightly bound in
crystallographic preparations, the nicotinamide portion was found to adopt multiple
conformations. However, none of the nicotinamide conformations were representative
of the catalytic form of the enzyme. First, the distances between nucleotide and FAD
were too great and more interestingly, access to the flavin was blocked by the
penultimate C-terminal residue, a tryptophan (Wang, Roberts et al. 1997).

Several

drawings based on the three-dimensional structure of P450 reductase are included in
Figs. 1.2-1.4 and illustrate the nucleotide binding pocket of the protein as well as the
key residues which are likely to determine nucleotide cofactor specificity.
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FIGURE 1.1 Cartoon illustrating the multi-domain structure of NADPH-cytochrome
P450 reductase.

NADPH

FAD

FMN

Membrane
anchor
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FIGURE 1.2 Space-filling drawing of NADPH-cytochrome P450 reductase with
FAD and FMN domains noted. The NADPH-binding region is outlined with the
adenine portion of the dinucleotide partially filling the pocket. The nicotinamide
portion of NADPH adopted multiple conformations in the crystal structure and is
not shown. The figure is adapted from Wang et al (Wang, Roberts et al. 1997).
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FIGURE 1.3 Ribbons diagram representation of NADPH-cytochrome P450
reductase with bound FAD, FMN, and the adenine portion of NADPH. This figure
was adapted from Wang et al. (Wang, Roberts et al. 1997).

FMN

FAD
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FIGURE 1.4 Diagram of the NADPH-binding domain of P450 reductase. Residues
mutated in these studies are labeled. Notice that serine 596, arginine 597, and
lysine 602 form a binding pocket for the 2'-phosphate of NADPH.

Also,

tryptophan 677 is shown in a conformation that would block productive binding
of the nicotinamide portion of NADPH. The figure is adapted from Wang et al
(Wang, Roberts et al. 1997).

FMN
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FAD

2'P
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R597 S596

Enzymology of Cytochrome P450 Reductase
Cytochrome P450 reductase donates reducing equivalents from NADPH to redox
partners such as the cytochromes P450. Two electrons are transferred from NADPH
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via hydride transfer to the FAD; FAD transfers single electrons to FMN. The acceptor
protein accepts two electrons one-at-a-time in a two electron reduction. Human P450
reductase cycles from the three electron reduced state to the one electron reduced
state (Figure 1.5), highlighting the importance of redox potentials of the flavins for
electron transfer. The reaction was determined by Sem and Kasper to be two-site pingpong with cytochrome c (Sem and Kasper 1994).
FIGURE 1.5 Electrons flow into NADPH-cytochrome P450 reductase from NADPH
by hydride transfer.

The reductase cycles between a three and one electron

reduced state. FAD accepts two electrons from NADPH, but FMN acts as a oneelectron donor/acceptor and shuttles single electrons to the target molecule.
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1e -

NADP+

P450RED

P450RED
FMNH
FADH2
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3e -

FM NH2
FADH
3e -

FM NH
FADH
P450OX

2e -

FM NH2
FAD
2e -

FM NH
FAD
P450OX

1e -

In the case of the cytochromes P450, in general, molecular oxygen is split: one
oxygen atom is reduced to water, the other used for carbon oxidation. The general
P450 reaction scheme is presented in Fig. 1.6, adapted from a review by F. P.
Guengerich (Guengerich 2001). The iron containing heme of P450 is bound to the
enzyme through four heme nitrogens, and also a cysteine, which causes the
characteristic absorbance maximum at 450 nm. Histidine ligand-heme proteins (e.g.
hemoglobin) have an absorbance maximum of 420 nm. In the absence of substrate,
the heme iron is in the ferric state. Substrate binding triggers a one electron reduction
from P450 reductase, leading to the formation of ferrous iron. Molecular oxygen then
becomes bound to the ferrous iron center. A second, one electron reduction from P450
reductase leads to splitting of the oxygen-oxygen bond, with the release of one atom as
water. The remaining oxygen-iron complex forms the reactive FeO3+ which is able to
oxidize substrate.

7

FIGURE 1.6 The reaction cycle of the typical cytochrome P450 cycle. NADPHcytochrome P450 reductase donates electrons in a two electron reduction of the
heme of P450. Molecular oxygen is split, one atom is utilized to oxidize substrate,
and the other atom is reduced to water. Figure adapted from an excellent review
of cytochrome P450 metabolism by F. P. Guengerich. (Guengerich 2001)

The physiologically relevant nucleotide cofactor for cytochrome P450 reductase
is NADPH. The reductase can be driven by non-physiological concentrations of NADH
in the millimolar range, while NADPH facilitates catalysis at low micromolar levels. The
ratio between the Km with NADPH versus the Km with NADH is higher for P450
reductase than that of other NADPH specific enzymes, see Fig. 1.7 (Sem and Kasper
1993). Understanding the nature of P450 reductase’s high selectivity for NADPH is one
of the primary aims of this research. The only chemical difference between NADPH and
NADH is the presence of a 2'-phosphate on the adenine ribose, as shown in Figs. 1.8
and 1.9.

Therefore, this phosphate must be a key factor in determining specificity
8

between the two nucleotides. This must also be true for other enzymes which are
specific for the nicotinamide adenine dinucleotide cofactors.

These nucleotides are

generally utilized differentially by cells; the NADH pool is important for catabolism and
the NADPH pool for anabolic reactions.
FIGURE 1.7 NADPH-cytochrome P450 reductase maintains high selectivity for
NADPH over NADH (Sem and Kasper 1993). Even among similar NADPH-utilizing
enzymes (Arnon 1965; Cove 1967; Huang, Appleman et al. 1990; Scrutton, Berry
et al. 1990), P450 reductase has unusually high specificity for the phosphatecontaining nucleotide.

9

FIGURE 1.8 NADPH and NADH differ only in the presence of a phosphate on the
number two carbon of the adenine ribose. In NADH this moiety is a hydroxyl
group.
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FIGURE 1.9 A space-filling drawing of NADPH. The 2'-phosphate creates a unique
shape and charge for nucleotide recognition.

Regulation of Cytochrome P450 Reductase
While there are many isoforms of cytochrome P450 enzymes in mammals, there
is only one protein responsible for donating electrons, NADPH-cytochrome P450
reductase.

P450 reductase is universally expressed, though the highest levels are

found in the liver. While many of the cytochromes P450 are highly inducible, P450
reductase is independently regulated and is present at basal levels.

The single

reductase gene is localized on human chromosome 7, and, like other house-keeping
genes, the promoter region lacks TATA and CCAAT boxes (O'Leary, Beck et al. 1994).
The GC-rich promoter region does contain nine consensus sequences for the SP1
transcription factor, however it appears that the proximal two sites are most important
for transcription, but are not absolutely required

(O'Leary, McQuiddy et al. 1996).

Furthermore, a thyroid response element was discovered by O’Leary and others
(O'Leary, Li et al. 1997). Indeed, hypophysectomy of adult male rats produces an 8085% decrease in liver P450 reductase protein levels, causing a drop of up to 85% in the
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level of P450 reductase activity, likely due to a decrease in observed P450 reductase
mRNA levels (Ram and Waxman 1992).
Knock-out Studies
Basic questions regarding the importance of functional P450 reductase were
addressed in recent reports that describe both the complete and conditional-hepatic
knock-out of the P450 reductase gene in mouse. Complete loss of the P450 reductase
gene results in embryonic lethality at day 11 of gestation, further characterized by
developmental abnormalities in the neural tube, cardiac, eye and limb (Shen, O'Leary et
al. 2002).

These results emphasize the important role P450 reductase plays in

providing electrons to enzymes important for development, including many involved in
cholesterol synthesis and breakdown, retinoic acid metabolism, and heme catabolism.
Conditional deletion of the P450 reductase gene in the liver of adult mice by the Cre/lox
system leads to an impaired ability to both generate cholesterol and to eliminate it
through bile acid synthesis, and is characterized by elevated hepatic lipids, reduced
serum cholesterol levels and reduced bile flow.

Furthermore, hepatic-null reductase

mice completely lost microsomal P450 function in the liver, resulting in a five-fold
induction of P450 enzymes with essentially no activity. Phenobarbital administration in
hepatic reductase-null mice induced prolonged sleep at a concentration that produced
no sleep in wild-type animals. Dosing of acetaminophen led to a 90% drop in hepatic
glutathione levels and a rise in serum indicators of liver failure in wild-type animals,
whereas glutathione levels and biomarkers of liver health remained stable in P450
reductase-null animals. Surprisingly, hepatic-null mice were able to survive and breed,
emphasizing the predominant role of the P450 system in xenobiotic metabolism in adult
liver (Henderson, Otto et al. 2003).
Bioremediation
A primary goal of this research is to develop mammalian enzyme systems with
improved activity in bacteria, which could lead to more effective bioremediation
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schemes.

Modification of P450 reductase to use both NADH and NADPH could

contribute to the effort to develop recombinant P450 systems in bacteria for chemical
degradation. Bioremediation is the use of biological agents to break down xenobiotics
in the environment.

Important factors affecting the potential for successful

bioremediation include the bioavailability of the target toxicant, subsequent transport
into cells with access to the appropriate metabolizing enzymes, or, alternatively, the
secretion of appropriate biodegradation enzymes, and the ability of cells to function
under in situ environmental conditions (Pieper and Reineke 2000). Intrinsic chemical
properties, such as stability of target compounds also play a role (Dua, Singh et al.
2002).

Nature has provided an enormous number of bacterial species capable of

degrading waste chemicals.

However, limitations include toxicity to biodegrading

organisms, low nutrient and oxygen levels in situ, and the lack of appropriate
metabolizing enzymes for complete degradation. The latter limitation can be addressed
with the use of genetically engineered microorganisms.
Over the last decade, many gene sequences for isoforms of the cytochromes
P450 have been discovered and published. Furthermore, many have been expressed
in bacteria along with P450 reductase to produce enzymatic activity comparable to that
seen in liver microsomes, see Guengerich et al. for a list (Guengerich, Parikh et al.
1997). In addition to bioremediation, applications of these systems include cytochrome
P450 structure-function analysis, screening of P450 substrates to generate profiles, and
bacterial mutagenicity assays (Guengerich and Parikh 1997).
If naturally occurring enzymes fail to provide the necessary enzymatic activity for
bioremediation, several techniques for improving enzyme turnover and/or chemical
specificity may be attempted. These methods include rational redesign by site-directed
mutagenesis based on genetic sequence alignments with similar enzymes and/or
structure data.

Random mutagenesis and gene shuffling, a.k.a. in vitro

gene

recombination, approaches compliment rational approaches, as long as there is an
effective screening technique available for sifting through the large numbers of proteins
generated (Guengerich 1995).
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Ethical issues regarding the introduction of genetically modified microorganisms
into the environment cloud the future of such tools for in situ bioremediation
(Guengerich 1995). However, only the creation of useful remediation tools including
genetically engineered bacteria will allow these ethical problems to be addressed.
Additional limitations to the use of genetically altered bacterial strains include the
expense of monitoring enzyme activity and engineered bacterial growth in situ and the
possibility of reduced survival rates among genetically modified bacteria (Sayler and
Ripp 2000). Monitoring introduced strains can be accomplished by PCR of recombinant
DNA or the mRNA transcripts (Pieper and Reineke 2000) or through bioluminescence
approaches (Dua, Singh et al. 2002).
Recombinant Cytochrome P450/Cytochrome P450 Reductase Systems
While expression of mammalian P450/reductase systems in bacteria has been
shown to be a valuable research tool and has promise as a tool for biodegradation
(Guengerich 1995), enzyme activity in recombinant bacterial systems appears to be
limited by glucose availability (Shet, Fisher et al. 1997). One explanation for this might
be that the generation of NADPH is largely dependent on the glucose shunt pathway,
which is operative primarily in high glucose environments. Supporting this hypothesis
are data from Bochner and Ames (Bochner and Ames 1982) that indicate that bacterial
NAD(H) levels exceed NADP(H) levels by approximately 4:1.

To address the

hypothesis that heterologously expressed P450 systems in bacterial cells are limited by
the availability of NADPH, I constructed a series of reductase proteins designed to use
NADH more efficiently. Specific mutations in the nicotinamide cofactor 2'-phosphatebinding site were generated based on the crystal structure of the reductase from rat
(Djordjevic, Roberts et al. 1995; Wang, Roberts et al. 1997), and from sequence
alignments of rat cytochrome P450 reductase (Porter and Kasper 1985) with other
NADPH- and NADH-specific reductases including spinach ferredoxin-NADP+ reductase
(Karplus, Daniels et al. 1991), nitrate reductases from Neurospora crassa (NADPH)
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(Okamoto, Fu et al. 1991), and corn (NADH) (Hyde and Campbell 1990), and NADHcytochrome b5 reductase (Yubisui, Naitoh et al. 1987), as shown in Fig. 1.10.
FIGURE 1.10 A sequence alignment between NADPH-cytochrome P450 reductase
and two related NADPH-specific enzymes along with two related NADH-specific
enzymes.

The functions of these amino acids have been studied previously in cytochrome
P450 reductase, as well as in the cytochrome P450 reductase homologues nitrate
reductase and ferredoxin-NADP+ reductase. For example, studies by Sem and Kasper
(Sem and Kasper 1993) have shown that arginine 597 of P450 reductase from rat plays
a critical role in binding the 2'-phosphate of NADPH, and thereby discriminating
between NADPH and NADH; substitution of this residue with methionine produced a
reductase with a greater than 100-fold higher Km value for NADPH, while the kcat for
NADPH remained at a level comparable to wild-type. The kcat and Km values for NADH
were similar between wild-type and the Arg597Met substitution (Sem and Kasper 1993).
However, substitution of serine or threonine for arginine 922 of NADPH-nitrate
reductase from Neurospora crassa, which corresponds to arginine 597 of P450
reductase, was shown by Shiraishi et al. to be unable to significantly alter the specific
activity (µmol/min) with either NADPH or NADH (Shiraishi, Croy et al. 1998).

This

indicates a fundamental difference in the amino acid residues that these two proteins
utilize to bind nucleotide cofactor.

Mutation of arginine 931 to glutamine in nitrate

reductase, which corresponds to lysine 602 of P450 reductase, led to a decrease in
NADPH specific activity (µmol/min) and an increase in NADH specific activity
15

(µmol/min); catalytic constants were not reported for this protein (Shiraishi, Croy et al.
1998). Substitution of aspartic acid for serine 921 in nitrate reductase had a large effect
on cofactor specificity, leading to 2% of wild-type specific activity (µmol/min) with
NADPH, but 15-fold greater specific activity (µmol/min) with NADH versus wild-type
(Shiraishi, Croy et al. 1998). These changes in specific activity were correlated with the
decrease in the catalytic efficiency (kcat/Km) for NADPH and an increase for NADH for
that protein.

Double substitution of S921D/R931S in nitrate reductase led to the

greatest switch in cofactor specificity, greater than 73,000-fold compared to wild type
(kcat/Km; NADPH/NADH; wild-type/mutant), but improved the catalytic efficiency
(kcat/Km) versus wild-type with NADH by only 2.5-fold (Shiraishi, Croy et al. 1998).
Similar studies have been carried out in ferredoxin-NADP+ reductase from
spinach, a closely related flavoprotein involved in NADPH production. Lysine 244 of
ferredoxin-NADP+ reductase, which corresponds to lysine 602 in P450 reductase, was
mutated to glutamine, increasing both the Km and the kcat with NADPH (Aliverti,
Lubberstedt et al. 1991), while NADH activity was not studied in this protein. These
comparisons indicate that although high sequence homology exists in the 2'-phosphate
binding regions of these closely related proteins, it is likely that three-dimensional amino
acid arrangements ultimately determine the function these residues serve.
Substitutions of the C-terminal tyrosine in ferredoxin-NADP+ reductase from pea
produced similar results to the W677A substitution with cytochrome P450 reductase
presented by Döhr et al. (Dohr, Paine et al. 2001), i.e. a decrease in Km and increase in
kcat for NADH (Orellano, Calcaterra et al. 1993), but lower Km and kcat for NADPH
(Orellano, Calcaterra et al. 1993; Piubelli, Aliverti et al. 2000).

Thus, although the

phosphate-binding amino acids differ between these proteins, aromatic C-terminal
residues probably perform a similar function in both enzymes in order to maintain
selectivity for NADPH over NADH. Döhr et al (Dohr, Paine et al. 2001) demonstrated
that tryptophan 677 appears to block access of the nicotinamide portion of the NADPH
cofactor to the flavin, and proposed that this amino acid plays a role in removal of
NADP+ after hydride transfer. This amino acid is suggested to contribute to cofactor
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specificity by blocking the nucleotide-binding site from both NADPH and NADH:
NADPH, with higher binding affinity due to a 2'-phosphate-binding pocket, is evidently
able to displace the tryptophan and form a productive electron-transfer complex,
whereas NADH cannot bind tightly enough to displace the tryptophan. Consistent with
this hypothesis, removal or substitution of W677 greatly increases turnover with NADH,
but leads to inhibition by NADP+. I hypothesized that mutations in the 2'-phosphatebinding site might reduce the affinity of the enzyme for NADP(H) and reduce or prevent
the inhibition by NADP+. Several highly conserved residues make up the 2'-phosphatebinding motif, including serine 596, arginine 597, and lysine 602; the position of these
amino acids in the NADP(H)-binding domain are shown in Fig. 1.4. The present studies
reveal that the combination of 2'-phosphate-binding site mutations with the W677A
substitution yields a cytochrome P450 reductase that uses NADH without inhibition by
NADP+. As any enzyme to be used in in vivo applications such as bioremediation must
retain activity in a mixed nucleotide environment, this reductase may prove useful in
such applications.
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CHAPTER TWO
GENERATION OF CYTOCHROME P450 REDUCTASE COFACTOR MUTANTS
Introduction to Site-Directed Mutagenesis
Site-directed mutagenesis is an important technique for protein structure-function
studies.

It allows selected amino acids in a protein to be replaced with either

conservative or nonconservative substitutions. Effects of amino acid substitutions can
be analyzed after subsequent expression and purification of these altered proteins or
after expression in intact cells. Several other tools make site-directed mutagenesis
studies more relevant and conclusive, including sequence alignments of closely-related
proteins, computer programs that predict structural motifs and techniques which directly
determine three-dimensional structure such as X-ray crystallography and NMR.
To test the hypothesis that NADPH might be limiting in bacterial cells expressing
a recombinant P450 system in vivo, I needed P450 reductase(s) that use NADH under
physiologically relevant conditions. Targeting amino acids outlined in Chapter One, I
used site-directed mutagenesis to substitute amino acids believed to be important for
nucleotide cofactor binding and recognition.
Generation of P450 Reductase Mutants
Site-directed mutagenesis was carried out in either pIN3OR6XHis, a P450
reductase bacterial expression plasmid in which a 6xhistidine tag was placed at the Nterminus of the reductase, or in pIN3ER plasmid coexpression vector containing the
cDNAs for rat P450 reductase and human P450 2E1 (Porter and Chang 1999). Whole
plasmid amplification (see Fig. 2.1) was performed as described in the QuickChange™
site-directed mutagenesis kit (Stratagene) with changes noted. Primers were designed
that contained the desired base changes necessary for the desired amino acid
substitution (Fig. 2.1; Step 1). Primers were designed to have a melting temperature
greater than or equal to 78°C.

Alternatively, the set of primers from above were
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combined with other primers and amplified by PCR to generate a longer primer for
whole plasmid amplification. These extended primers generally had a length between
100 and 500 base pairs and contained the desired base changes.

These longer

primers were generally more efficient in producing whole plasmid amplification. PCR
reactions contained 5-50 ng of plasmid template DNA, 50 pmols of each primer or 2 µL
of PCR product incorporating mutations, deoxynucleotide triphosphates (dNTPs) (200
µM), 2.5 units of Pfu Turbo Polymerase (Stratagene), Pfu Turbo Polymerase buffer, and
double deionized water (ddH2O) to 50 µL total volume. Ninety-five degrees Celsius was
used to melt template DNA, ~55°C was used as the annealing temperature, and ~68°C
was used for extension. Pfu polymerase generally incorporates dNTPs at a rate of 1-2
minutes/kilobase of template. Therefore, for pIN3OR6xHis (~9,500 bp) and pIN3ER
(~11,000 bp) extension times of 19 and 22 min were used.
carried out in a Perkin-Elmer 2400 thermocycler.

Eighteen cycles were

Products of amplification were

visualized on a 1% agarose gel with ethidium bromide. Ten units of Dpn I were added
to digest methylated parental template DNA (Step 2). One to five µL of the reaction
mixture was transformed into chemically competent E. coli (Step 3).
screened by sequencing.
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Clones were

FIGURE 2.1 Mutagenesis by whole plasmid amplification.

1

2

3
1. PCR
2. + Dpn I
3. Transformation
Subcloning is a method of moving sections of double-stranded DNA from one
vector to another, as depicted in Fig. 2.2. I used it rarely because of the ease of whole
plasmid amplification, but occasionally when I wanted to introduce a mutation into a
plasmid vector or, more commonly, to combine mutations that were far enough apart on
their plasmid vector that a unique restriction site was located between the mutations.
This allowed one mutation to be excised, purified, and ligated into a plasmid vector
containing the second mutation. Generally, between 100-1,000 ng of plasmid DNA was
digested with restriction endonucleases (2-10 U) (Step 1). These restriction enzymes
were both compatible in the same buffer, or the DNA was purified to remove buffer and
a second buffer was added. Five-prime phosphates were removed from vector DNA to
prevent religation of incompletely digested plasmid DNA, as follows:

Alkaline

phosphatase (10 U) was added directly to the original restriction digest and incubated
for 1 hour at 37°C. Phosphatase activity was terminated by addition of 2 µL 0.5 M
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EDTA followed by incubation at 65°C for 20 min. Insert DNA was separated by 1%
agarose gel, and the band was excised with a razor blade (Step 2). Gel pieces were
spun in a 0.45 µm nylon membrane centrifugal spin tube (Costar) and collected in 1x
TAE.

DNA was visualized on a 1% agarose gel to determine quantitation.

Dephosphorylated vector was then added to insert at a 1:3 molar ratio with ligase (1U)
and incubated overnight a 4°C (Step 3).

Two µL of the ligation reaction was

transformed into chemically competent E. coli and positive clones were identified by
DNA sequencing.
FIGURE 2.2 Mutagenesis by sub-cloning.
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3

1. Digest
2. Purify fragments
3. Ligate

Mutagenesis by overlap-extension (Fig. 2.3) allows multiple changes to primary
genetic sequences or the creation of chimeric constructs by targeted splicing of two
unique DNA sequences to create proteins with new and interesting activities. Primers
are designed that incorporate the desired mutations (or the novel DNA to be joined) at
the five prime ends. These “inside” primers are combined with “outside” primers to
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create templates that overlap at positions found in the five prime ends of the “inside”
primers.

An eight-amino acid substitution was introduced by overlap-extension

polymerase chain amplification as described (Slack 1998) to generate a reductase with
the following substitutions: S596D, R597R, E598A, Q599P, A600E, H601A, K602W,
and V603D. Two chimeric proteins were designed, containing the NADH-binding region
of b5 reductase in place of the NADPH-binding region of P450 reductase. One chimera
contained the “linker-arm” of P450 reductase, and was named “OR/b5R-short”. The
other chimera contained the connecting region of b5 reductase, and was named
“OR/b5R-long”.

OR/b5R-short was cloned and confirmed by DNA sequencing, yet

failed to yield protein sensitive to P450 reductase antibody. The OR/b5R-long construct
was designed, but was never completed for expression experiments. All mutations were
confirmed by sequencing.
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FIGURE 2.3 Mutagenesis by overlap-extension polymerase chain reaction.
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Purification and Quantitation of Proteins
With all constructs, a fresh colony was selected for protein expression and grown
overnight in LB media at 37°C. Overnight culture was used to inoculate up to 6 liters of
Terrific Broth at 37°C followed by the addition of 1 mM isopropyl β-D-1thiogalactopyranoside (IPTG) when the O.D.600 reached 0.8; culture was continued
23

overnight at 30°C with shaking (125 rpm). Cells were harvested by centrifugation and
the membrane fraction was isolated and solubilized as described (Porter and Chang
1999), omitting the dithiothreitol and 4-methylpyrazole. Cells were lysed by French
press in buffer consisting of 20 mM KPO4 (pH 8.0) and 50 mM KCl. The lysate was
clarified at 10,000 x g, and a second supernatant fraction was obtained by centrifugation
at 100,000 x g. The membrane pellet was resuspended in a glass dounce homogenizer
with a type B pestle in 5 mL of 10 mM Tris-Acetate (pH 8.0) and 20% glycerol.
Solubilization of membranes was carried out on ice with stirring by addition of Triton X100 dropwise to 1%. Solubized membranes were then clarified at 100,000 x g and the
supernatant used for affinity purification.
Wild-type P450 reductase and mutants were purified by metal affinity
chromatography using TALON IMAC metal affinity resin (Clontech) as shown
schematically in Fig. 2.4. Typically 3 mL of metal affinity resin (1.5 mL column volume)
in ethanol was added to a 10 mL plastic column (Biorad). The column was equilibrated
in twenty bed volumes of column buffer: 300 mM NaCl, 50 mM NaPO4 (pH 8.0), 1%
Triton X-100, and 10% glycerol. Solubilized membranes were added to the column and
recycled several times for maximum binding. Twenty column volumes of column buffer
were used to wash away unbound material. Proteins were eluted in column buffer plus
150 mM imidazole (pH 8.0), and stored in the same buffer at -20°C.
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FIGURE 2.4 An illustration of the purification of NADPH-cytochrome P450
reductase and mutant enzymes.

Results of Protein Expression/Purification Experiments
The purified proteins were largely homogeneous, and migrated with a molecular
weight of 78.5 kDa, as did wild-type reductase (Fig. 2.5); immunoblotting with antibody
to P450 reductase indicated that the lower molecular weight contaminants were
predominantly reductase degradation products (Fig. 2.6). Reductase was quantified by
boiling to release the flavins and measuring the absorbance at 450 nm using an
extinction coefficient of 23.5 mM-1 (Vermilion and Coon 1978), see Fig. 2.7.
Purification of Squalene Monooxygenase
Purification of squalene monooxygenase was performed as described by Laden
et al. (Laden, Tang et al. 2000).

The cDNA encoding squalene monooxygenase,

lacking the first 330 base pairs, from human was cloned previously (Laden, Tang et al.
2000) into the pTYB4 expression vector, part of the IMPACT T7 System (Clontech)
which expresses the enzyme along with an intein protein splicing element from yeast
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and a chitin binding domain.

Bacterial cells were lysed by French press in buffer

containing 20 mM Tris-HCl (pH 7.4), 500 mM NaCl, 0.1 mM EDTA, and 0.1% Triton X100, and centrifuged at 12,000 x g. The supernatant was loaded on a chitin column
equilibrated in the same buffer. Following washing by 20 bed volumes of buffer, the
column was incubated with buffer containing 30 mM β-mercaptoethanol overnight at
4°C. Squalene monooxygenase was eluted and buffer changed to 20 mM Tris-HCl (pH
7.4), 0.1% Triton X-100 by centrifugal dialysis and stored at -80°C.

Enzyme was

quantified with the Coomassie Plus Protein Assay Reagent Kit (Pierce).
FIGURE 2.5 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis of P450
reductase mutants. Affinity-purified reductase proteins were fractionated on an
8.75% polyacrylamide gel and stained with Coomassie blue. Lane 1, molecular
mass standards at 221, 133, 93, 67, 56, 42, and 28 kDa; 2, wild-type reductase; 3,
S596D; 4, R597M; 5, K602W; 6, SD/WA; 7, SD/KW; 8, W677A; 9, RM/WA; 10,
KW/WA; 11, 8 amino acid substitution; 12, RM/KW; 13, RM/KW/WA; and 14,
SD/WA.
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FIGURE 2.6 Western blots of P450 reductase mutants. Lane 1, molecular mass
standards at 221, 133, 93, 67, 56, 42, and 28 kDa; 2, wild-type reductase; 3, S596D;
4, R597M; 5, E598A; 6, K602W; 7, molecular mass standards; 8, SD/RM; 9, SD/KW;
10, W677A; 11, RM/WA; 12, KW/WA.
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FIGURE 2.7 Flavin spectra of wild-type P450 reductase and mutant proteins.
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A Comparison between Native Cytochrome P450 Reductase and the 6x-histidine
Tagged P450 Reductase Construct
A 6x-histidine tag allows easy, often single-step, column-affinity purification of
proteins.

However, the addition of six additional histidine residues at the N- or C-

terminus may alter protein function. Many newer 6x-histidine tag vectors allow the
removal of the 6x-histidine tag after affinity purification using a thrombin-cleavage site.
However, this technique invariably yields proteins with additional non-native amino
acids at the cleavage site. In order to address this concern with 6x-histidine tagged
P450 reductase clones, aniline hydroxylation experiments were carried out with wildtype and 6x-histidine tagged P450 reductases with cytochrome P450 2E1. Reductase
concentrations were varied, with all other variables held constant, in order to generate
Km and Vmax numbers for the two proteins. Results of these experiments are shown in
Table 2.1.
Cytochrome P450 reductase was purified by 2'5'-adenosine diphosphate agarose
affinity chromatography.

Wild-type proteins were eluted in 50 mM Tris (pH 7.7),

containing 0.1 mM EDTA, 10% glycerol and 2 mM 2'-adenosine monophosphate. Wildtype reductase was quantified by boiling an aliquot and measuring the flavin
absorbance at 450 nm. 6x-histidine tagged reductase protein was purified as described
in detail earlier in this chapter.
expressed in E. coli.

Cytochrome P450 2E1 protein from rabbit was

Membranes were solubilized in octyl-glucoside detergent.

Proteins were changed into phosphate buffer (pH 7.4) containing 1 mM EDTA and 20%
glycerol. Cytochrome P450 2E1 was quantified by carbon monoxide difference spectra
measuring heme at 450 nm.

Aniline hydroxylation assays contained 10-150 pmols

reductase, 50 pmols P450 2E1, 1 mM NADPH, and 2.5 mM aniline in the phosphate
buffer described above.

Reactions were initiated by addition of NADPH and were

incubated at 37°C for 0, 15 and 30 minutes to determine reaction rates.

para-

Aminophenol production was measured as an increase in absorbance at 630 nm using
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an HP 8453 spectrophotometer. Michaelis-Menten kinetic constants were determined
using GraphPad Prism 3.
These enzyme assays show that wild-type cytochrome P450 reductase and the
6x-histidine tagged reductase are not statistically different in their ability to stimulate the
hydroxylation of aniline to para-aminophenol. Additionally, during purification, both wildtype and 6x-histidine tagged reductase were found to be inserted into bacterial
membranes, suggesting the N-terminal 6x-histidine tag did not alter the enzyme
conformation significantly enough to alter the ability of the N-terminal membrane binding
domain to function correctly.

Therefore, 6x-histidine tagged P450 reductase is

considered to be functionally the same as wild-type for these experiments.
TABLE 2.1 A comparison between wild-type and 6x-histidine tagged reductases.
Kinetic constants derived from reductase-supported hydroxylation of aniline by
P450 2E1, in vitro. Values represent best fits ± S.D.

Mutant

Km (nM reductase)

Vmax (nmols p-AP/hr)

WT

22.6 ± 3.0

17.4 ± 0.8

6x-histidine Tag

14.9 ± 3.8

15.2 ± 1.0
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CHAPTER THREE
ACTIVITY ANALYSIS OF CYTOCHROME P450 REDUCTASE
MUTANTS WITH CYTOCHROME C
Introduction to Cytochrome c Reductase Activity Assays
P450 reductase proteins with altered cofactor specificity were evaluated with the
non-physiological electron acceptor cytochrome c. Michaelis-Menten kinetic constants
were determined with each enzyme.

Comparisons between Km, kcat and catalytic

efficiency (kcat/Km) allowed a means of objectively evaluating the effects of amino acid
substitutions. Cytochrome c is inexpensive, stable and readily accepts electrons from
P450 reductase. The rate of reduction of the bound heme of cytochrome c can be
measured at 550 nm.
Steady State Kinetics with Cytochrome c
Km and kcat determinations were carried out with 60 µM cytochrome c from horse
heart (Sigma) in 100 mM Tris, pH 8.0 with an ionic strength of 0.75 M with KCl.
Reactions were started by the addition of nucleotide cofactor (NADPH or NADH) and
were monitored for 40 seconds at room temperature on an HP 8453 spectrophotometer
(Hewlett-Packard), following the absorbance change at 550 nm.

An extinction

coefficient of 21.1 mM-1 was used to quantitate cytochrome c reduction (Vermilion and
Coon 1978). Catalytic constants were estimated by non-linear regression using Prism
(GraphPad Prism 3).
Results of Cytochrome c Reductase Assays
I generated mutants of cytochrome P450 reductase that have decreased
specificity for the physiological cofactor NADPH.

These mutants fall into three

categories: those containing mutations in the 2'-phosphate-binding region of NADPH; a
single mutant in which tryptophan 677, which is positioned directly opposite of the FAD
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isoalloxazine ring, is replaced with alanine; and double and triple combinations of these
two. As expected, single and double substitutions in the 2'-phosphate-binding region
yielded proteins with greatly reduced catalytic efficiency (kcat/Km) with NADPH (Table
3.1). A comparison of catalytic constants of P450 reductase proteins is shown in Figs.
3.1-3.4. The R597M, S596D, K602W, and R597M/K602W proteins showed a 40- to
13,000-fold increase in the Km for NADPH as compared to wild-type with cytochrome c
as the electron acceptor, with the K602W substitution having the least effect on Km and
the S596D mutation producing the highest Km. Of these mutants, the S596D showed
the most profound decrease in the kcat with both NADPH and NADH, indicating an
overall detrimental effect on electron transfer; all of the mutants containing S596D had
little or no activity with either cofactor. Proteins with the R597M substitution (R597M
and R597M/K602W) maintained turnover numbers with NADPH and NADH that were
comparable to that of the wild-type enzyme, whereas the K602W mutation decreased
turnover with both cofactors in the absence of the R597M substitution. As an alternative
to individual substitutions, the segment from S596 to V603 (8 amino acids) was
replaced with the corresponding segment from NADH-cytochrome b5 reductase, a
closely related NADH-dependent flavoprotein (Yubisui, Naitoh et al. 1987).

The

resulting mutant protein bound flavin but had no observable cytochrome c reductase
activity. Considering that this protein bound flavin, the lack of activity was most likely
due to alterations of the secondary structure of the 2'-phosphate binding pocket, such
that productive nucleotide binding was lost.
The W677A mutant retained only 1.2% of wild-type activity (kcat) with NADPH,
while the Km for NADPH remained similar to wild-type when assayed with cytochrome c.
In contrast, the W677A mutant had a kcat with NADH that was approximately 3-fold
higher than that of wild-type with NADH, while the Km of NADH decreased by
approximately 250-fold. The W677A enzyme also showed the most profound change in
NADH catalytic efficiency with a greater than 700-fold increase versus wild-type.
Coupled with a decrease in catalytic efficiency with NADPH of 74-fold, it is apparent that
this single amino acid contributes remarkably to cofactor specificity for NADPH versus
NADH in wild-type P450 reductase.
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Proteins

containing

altered

2'-phosphate-binding

domains

and

W677A

substitution showed kinetics resembling the W677A mutation alone. However, the Km
for NADPH was significantly increased compared to wild-type in the K602W/W677A,
R597M/W677A, and R597M/K602W/W677A proteins by 1.5, 2.4, and 54-fold,
respectively. With NADH, conversely, the Km values for these proteins remain similar to
the W677A alone. Turnover numbers with the combined substitutions with NADH are
lower

than

the

W677A

enzyme.

However

with

the

R597M/W677A

and

R597M/K602W/W677A proteins, kcat values remain equal to or greater than wild-type
with NADH. With NADPH, a 4-, 7-, and 43-fold decrease in kcat values is seen with the
R597M/K602W/W677A, R597M/W677A, and K602W/W677A proteins, respectively.
FIGURE 3.1 Comparison of Km values for 2'-phosphate-binding mutant reductase.
ND indicates no detectable activity. WT, wild-type P450 reductase; SD,
Ser596Asp; RM, Arg597Met; KW, Lys602Trp.
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ND ND

SD/RM SD/KW RM/KW

FIGURE 3.2 Comparison of Km values for mutant reductases containing the
Trp677Ala substitution. ND indicates no detectable activity. . WT, wild-type P450
reductase; SD, Ser596Asp; RM, Arg597Met; KW, Lys602Trp; WA, Trp677Ala;
R/K/W, Arg597Met/Lys602Trp/Trp677Ala.
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FIGURE 3.3 Comparison of kcat values for 2'-phosphate-binding mutant
reductases. ND indicates no detectable activity. WT, wild-type P450 reductase;
SD, Ser596Asp; RM, Arg597Met; KW, Lys602Trp.
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FIGURE 3.4 Comparison of kcat values for mutant reductases containing the
Trp677Ala substitution. ND indicates no detectable activity. WT, wild-type P450
reductase; SD, Ser596Asp; RM, Arg597Met; KW, Lys602Trp; WA, Trp677Ala;
R/K/W, Arg597Met/Lys602Trp/Trp677Ala.
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RM/WA

KW/WA

R/K/W

TABLE 3.1 Catalytic activities of P450 reductase mutants with NADPH and NADH. The values represent
best fits ± S.D.  indicates lack of measurable activity.

NADPH
kcat
-1

Km

NADH
kcat/Km
-1

kcat
-1

-1

Km

kcat/Km
-1

NADPH/NADH
-1

(min )

(µM)

(min *µM )

(min )

(µM)

(min *µM )

(kcat/Km/kcat/Km)

3,280 ± 50

1.6 ± 0.1

2,000

1,210 ± 140

27,600 ± 4,600

0.044

45,000

S596D

140 ± 9

20,600 ± 2,000

0.007

101 ± 6

10,100 ± 1,300

0.010

0.7

R597M

2,980 ± 70

156 ± 10

19

1,350 ± 110

14,100 ± 2,200

0.10

200

E598A

2,390 ± 90

0.8 ± 0.2

3,000

1,250 ± 110

13,200 ± 2,300

0.09

30,000

K602W

1,110 ± 20

64.0 ± 3.2

17

101 ± 4

5,330 ± 630

0.019

900

W677A

38 ± 3

1.4 ± 0.4

27

3,220 ± 70

103 ± 8

31.2

0.9

S596D/R597M







199 ± 40

12,300 ± 5,000

0.02



S596D/K602W















R597M/K602W

2,830 ± 140

3,900 ± 440

0.73

819 ± 129

18,500 ± 4,900

0.044

16

S596D/W677A















R597M/W677A

468 ± 13

3.8 ± 0.4

120

2,040 ± 80

99 ± 14

21

5.7

K602W/W677A

77 ± 3

2.5 ± 0.6

31

370 ± 16

168 ± 22

2.2

14

920 ± 22

87 ± 9

11

1,190 ± 30

162 ± 12

7.3

1.5















Mutant
WT

R597M/K602W/W677A
8 Amino Acid Sub.
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Glutamic Acid at Position 598 has a Limited Role in Determining Cofactor Specificity
Several reductase clones were generated that did not warrant extensive study or
discussion. These include a P450 reductase clone containing alanine substituted for
glutamic acid at position 598, the importance of which was suggested by its semiconserved appearance at this position in sequence alignments with similar NADPHspecific enzymes (Fig. 1.10).

This mutation lowered the Km by approximately one-half

with both NADPH and NADH in cytochrome c reductase assays (Table 3.2) when
compared to wild-type P450 reductase. When combined with the Ser596Asp mutation
a similar decrease in Km with both nucleotides was seen compared to the Ser596Asp
alone. The kcat values of Glu598Ala and the Ser596Asp/Glu598Ala reductases were not
considered statistically different from wild-type or Ser598Asp, respectively, with either
nucleotide. The modest overall degree of change seen with the Km values and lack of a
significant effect on kcat values, coupled with the fact that similar effects were seen with
both NADPH and NADH, suggested a limited role for the glutamic acid 598 in
influencing cofactor specificity.

A triple mutant reductase containing Ser596Asp,

Arg597Met and Trp677Ala substitutions was also generated. However, consistent with
other reductases containing the Ser596Asp substitution, this protein had negligible
ability to reduce cytochrome c with either nucleotide cofactor.
TABLE 3.2 Catalytic activities of P450 reductases containing the Glu598Ala
substitution. The values represent best fits ± S.D.
NADPH

NADH

Mutant

Km (µM)

kcat (min-1)

Km (µM)

kcat (min-1)

WT

1.6 ± 0.1

3,280 ± 50

27,600 ± 4,600

1,210 ± 140

E598A

0.8 ± 0.2

2,390 ± 90

13,200 ± 2,200

1,250 ± 110

S596D

20,600 ± 2,000

140 ± 9

10,100 ± 1,300

101 ± 6

S596D/E598A

9,300 ± 1,800

176 ± 16

5,900 ± 2300

62 ± 9
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CHAPTER FOUR
INHIBITION OF P450 REDUCTASE MUTANTS BY NADP+
NADP+ as an Inhibitor of Cytochrome c Reductase Activity
As demonstrated by Döhr et al. (Dohr, Paine et al. 2001), substitution of the
penultimate amino acid in P450 reductase with alanine (W677A) produces a reductase
with 1000-fold higher specificity for NADH than NADPH.

Despite this remarkable

increase in turnover with NADH, the most striking feature of the W677A mutant is that it
is highly inhibited by NADP+ (Dohr, Paine et al. 2001). This inhibition is illustrated in
Figure 4.1 with a W677A mutant I constructed.

The following experiments were

designed to evaluate the effect of combining 2'-phosphate binding mutations with the
W677A enzyme on inhibition by NADP+.

Results of these experiments are shown in

Fig. 4.2.
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FIGURE 4.1 Inhibition of W677A Reductase by NADPH. Graph indicates
enzymatic activity of wild-type and W677A reductases with cytochrome c.
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NADP+ Inhibition Experiments
Assays were carried out in 100 mM Tris (pH 8.0), 0.75 M ionic strength with KCl,
60 µM cytochrome c, and varying concentrations of NADP+. Reactions were carried out
for 90 seconds and were monitored on a Hewlett Packard 8453 diode array
spectrophotometer.

Reduction of cytochrome c was monitored at 550 nm using a

millimolar extinction coefficient of 21.1 mM-1.
NADP+ Inhibition Results
The mutations in the phosphate-binding region described in Chapter 3 were
combined with the W677A substitution in order to overcome the profound inhibition by
NADP+.

I combined the S596D, R597M, and K602W mutants, as well as the

R597M/K602W double mutant, with W677A. Consistent with the other S596D mutants,
S596D/W677A produced a reductase with little or no activity with either cofactor.
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However, the R597M/W677A, K602W/W677A, and R597M/K602W/W677A proteins
were active and displayed reduced catalytic efficiency with NADPH as compared to
wild-type and increased catalytic efficiency with NADH (Table 3.1).

Of these three

proteins, the triple mutant (R597M/K602W/W677A) showed a 30,000-fold change in
cofactor specificity (catalytic efficiency). Inhibition of cytochrome c reduction by NADP+
was determined with these proteins and compared to that of wild-type reductase (Fig.
4.2). With the W677A protein, inhibition by NADP+ increased approximately 125-fold,
from an IC50 of 17.4 µM (wild-type) to an IC50 of 138.3 nM. Addition of the R597M
mutation to the W677A protein returned inhibition by NADP+ to a level comparable to
wild-type

reductase.

Inhibition

by

NADP+

was

greatly

decreased

in

the

R597M/K602W/W677A protein to an IC50 of 870 µM, 50-fold higher than the IC50 for
wild-type reductase.
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FIGURE 4.2 Reversal of inhibition by NADP+.
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The results of experiments outlined here characterize the inhibition by NADP+, a
product of wild-type P450 reductase catalysis. A reductase useful for in vivo
applications should retain maximal activity in a mixed-nucleotide environment (NADPH
and NADH). The W677A substitution creates a reductase strongly activated by NADH,
but inhibited by NADP+ at a concentration two orders of magnitude lower than the wildtype reductase. The additional substitution of arginine to methionine at position 597
lowers inhibition to that seen with the wild-type reductase, indicating that the binding of
the 2'-phosphate of NADPH is an important component for NADP+-mediated inhibition.
The double substitution protein (R597M and K602W) is inhibited by millimolar
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concentrations of NADP+, a level much greater than wild-type, further emphasizing the
importance of phosphate-binding residues in cofactor specificity.
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CHAPTER FIVE
ACTIVITY ANALYSIS OF CYTOCHROME P450 REDUCTASE MUTANT PROTEINS
WITH SQUALENE MONOOXYGENASE AND P450 1A2
Activity of P450 Reductase Proteins with Physiological Redox Partners
Cytochrome c is an ideal substrate, as discussed in Chapter Two, for monitoring
the kinetic activity of P450 reductase in vitro.

However, cytochrome c is not a

physiological redox partner for the reductase. In fact, cytochrome c is proposed to have
a different binding site on P450 reductase than the cytochrome P450s (Shen and
Kasper 1995). Assays utilizing physiological redox partners were needed to show that
activities of cofactor substitution mutants characterized by cytochrome c are not unique
to that substrate.
Squalene monooxygenase is an FAD-containing protein that catalyzes the
addition of an oxygen atom across the 2,3-double bond of squalene, a linear 30-carbon
intermediate in the cholesterol biosynthesis pathway, and is dependent on P450
reductase for reducing equivalents. The product of the reaction is 2,3-oxidosqualene,
which can be separated from squalene by thin layer chromatography and radiolabel
visualized by electronic autoradiography.

Cytochrome P450 1A2, with reducing

equivalents from P450 reductase, catalyzes the O-deethylation of ethoxyresorufin to
resorufin. Resorufin is a highly fluorescent molecule and its formation can be monitored
by fluorescence spectroscopy.
Squalene Monooxygenase Assays
Squalene monooxygenase assays were carried out as described (Laden, Tang et
al. 2000) based on the method of Bai and Prestwich (Bai and Prestwich 1992).
Reactions contained 20 mM Tris-HCl (pH 7.4), 0.1% Triton X-100, 30 µM FAD, 1mM
NADPH, 28 pmols of cytochrome P450 reductase, and 19 pmols of squalene
monooxygenase in 200 µL total volume. Incubations were started by the addition of 8
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nmols of C14-labeled squalene and were carried out for 30 minutes at 37°C. Reactions
were stopped by extraction into methylene chloride and separated by thin layer
chromatography on silica plates (Whatman) in 5% ethyl acetate in hexane. Plates were
counted by electronic autoradiography on a Packard Instant Imager.
Cytochrome P450 1A2 Assay: Ethoxyresorufin O-deethylase Activity (EROD)
Purified human P450 1A2 was obtained from Oxford Biomedical and activity was
determined by measuring deethylation of ethoxyresorufin (Sigma) to resorufin, as
described (Burke and Mayer 1974).

Incubation mixtures (2 ml) contained 2 µM

ethoxyresorufin, 42 pmols of P450 1A2, 40 pmols reductase, 1 mM NADPH and/or
NADH, and 0.1 µg/µl of phosphatidylcholine in 100 mM potassium phosphate buffer, pH
7.7. Following a 5-min preincubation at 37°C, reactions were started by the addition of
cofactor and resorufin fluorescence was recorded for 15 minutes with an excitation
wavelength of 510 nm and an emission wavelength of 586 nm. Turnover rates were
calculated from linear time points.
P450 Reductase Mutants Activate Physiological Redox Partners
I determined the ability of the wild-type and three mutant proteins to support
squalene monooxygenase activity with both NADPH and NADH (Fig. 5.1). Consistent
with the results obtained with cytochrome c, the W677A protein showed limited activity
with NADPH, having only ~13% of the activity of wild-type reductase. The addition of
the R597M substitution to the W677A protein restored full activity with NADPH, while
the further addition of the K602W substitution (R597M/K602W/W677A) reduced activity
with NADPH to approximately 28% of wild-type activity.

With NADH, the wild-type

reductase supported squalene monooxygenase only poorly, and the W677A protein
was only slightly more active. However, the double and triple mutants were 2.7- and
2.3-fold more active with NADH than the W677A mutant.
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Activity (pmols/min)

FIGURE 5.1 Activation of squalene monooxygenase by reductase mutants.
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Cytochrome P450 1A2 catalyzes the O-deethylation of ethoxyresorufin, and the
sensitivity of this assay made it ideal for further evaluation of reductase mutations. The
results of these experiments are shown in Fig. 5.2.

All mutant proteins showed

significantly lower deethylase activity with NADPH than wild-type. With NADH all the
mutants showed similar activity, roughly twice the activity of wild-type with NADH. To
explore how these mutants might fare in a mixed cofactor environment, we determined
EROD activity with equal concentrations of NADPH and NADH (1 mM). The W677A
reductase exhibited only 3.5% of wild-type activity, despite the presence of ample
NADH, indicating a marked inhibition by NADP+. In contrast, the R597M/W677A and
R597M/K602W/W677A proteins showed activity levels approaching those seen with
NADPH or NADH alone, indication that inhibition by NADP+ was not a factor.
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FIGURE 5.2 O-deethylation of ethoxyresorufin by CYP 1A2 and P450 reductase
mutants.
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RM/KW/WA

CHAPTER SIX
ACTIVITY ANALYSIS OF CYTOCHROME P450 REDUCTASE MUTANTS IN A
RECOMBINANT AMES TEST
The Recombinant Ames Assay
The traditional Ames assay, depicted in Fig. 6.1, is a valuable tool for screening
compounds which might be capable of causing mutations to DNA. The assay utilizes
Salmonella typhimurium strains that are incapable of growth in media lacking histidine.
This is due to a mutation in several genes necessary for the biosynthesis of histidine
(Venitt and Parry 1984). These mutations are, depending on the strain, frameshifts or
base pair substitutions. Reversion mutations which restore the ability to synthesize
histidine are caused by DNA damaging chemicals. Because many compounds must be
metabolized to their mutagenic form, mammalian enzymes must be added to the Ames
test. The traditional Ames assay typically utilizes a rat liver homogenate (S9 fraction)
for bioactivation of compounds. The make-up of this homogenate is typically poorly
characterized and contains a mixture of enzymes normally present in rat liver. One
limitation of the traditional Ames test is false negative results; e.g. when a chemical
such as dimethylnitrosamine, which is a known human carcinogen, fails to generate a
positive Ames test. This may be due to either to lack of the appropriate activating
enzyme in the S9 or to DNA repair in tester bacteria. To address the first possibility
recombinant plasmids which carry the cDNAs for expression of mammalian
metabolizing enzymes (CYP 2E1 and P450 reductase) were constructed (Porter and
Chang 1999), see Fig. 6.2; CYP 2E1 is believed to be the primary activator of
dimethylnitrosamine, in vivo. However, cells transformed with a plasmid coexpressing
CYP2E1 and P450 reductase failed to generate a positive Ames test (Cooper and
Porter 2000). To address the possibility that the dimethylnitrosamine-induced mutations
were being repaired, further studies were carried out in strains of S. typhimurium which
lack, due to chromosomal deletion, one or both of the O6-methylguanine DNA
methyltransferase genes ogtST and adaST (YG7104 ogt- and YG7108 ogt-, ada-)
(Yamada, Matsui et al. 1997).

With these strains and expression plasmid, a
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recombinant Ames test which is sensitive to dimethylnitrosamine was developed
(Cooper and Porter 2000).

This system allowed me to explore properties of P450

reductases that are able to utilize NADH in an “in vivo” setting. Furthermore, I could test
the hypothesis that NADPH levels limit turnover of P450 reductase in vivo.
FIGURE 6.1 Traditional Ames assay.

Salmonella

Low Dose

Medium Dose
Mutagen

High Dose
Mix with Top Agar
Microsomes

The Recombinant Ames Assay: Materials and Procedures
The activation of dimethylnitrosamine in Salmonella typhimurium strain YG7108
was carried out as described (Cooper and Porter 2000) with pIN3ER plasmids
expressing human cytochrome P450 2E1 and either wild-type rat cytochrome P450
reductase or the R597M/W677A, or R597M/K602W/W677A mutant proteins. Single
colonies obtained from electroporation of pIN3ER WT and mutant plasmids were used
to inoculate overnight cultures in LB media 100 µg/mL ampicillin with IPTG-mediated
induction of protein expression. Cells were mixed with increasing concentrations of
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dimethylnitrosamine in top agar and plated onto histidine-deficient Vogel-Bonner plates.
After incubation for 48 hours at 37°C, visible colonies were counted.
FIGURE 6.2 Recombinant Ames assay.

Salmonella

Low Dose
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Mutagen

Mix with Top Agar

High Dose

Plasmid for expression
of P450 2E1 and
P450 reductase
P450 Reductase Proteins Activate P450 2E1 in vivo
To evaluate the effectiveness of the mutant reductases in vivo, each was
coexpressed with cytochrome P450 2E1 in Salmonella typhimurium mutagenicity tester
strains. The number of revertants generated with dimethylnitrosamine, a mutagenic
substrate activated by P450 2E1, was determined with each reductase protein (Fig.
6.3). Bacteria containing the R597M/W677A reductase yielded nearly twice as many
revertants as wild-type, suggesting that the improved ability to use NADH increased
turnover and mutagen activation.

Bacteria containing the R597M/K602W/W677A

reductase showed very little mutagen activation, and this was shown to be due to very
low protein expression (Fig. 6.4).
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FIGURE 6.3 Activation of dimethylnitrosamine by CYP 2E1 and reductase
proteins, in vivo. WT, wild-type; RM/WA, Arg597Met/Trp677Ala; RM/KW/WA,
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FIGURE 6.4 Western blot of P450 reductase WT, RM/WA and RM/KW/WA
expression in YG7108 Salmonella typhimurium used in a recombinant Ames test.
Lane 1, affinity purified wild-type reductase; 2, pIN3ER WT whole cell lysate; 3,
pIN3ER RM/WA; 4, pIN3ER RM/KW/WA.
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NADH-utilization May Offer an Advantage in the Recombinant Ames Assay
The Ames tests data presented above suggest that NADPH might be limiting
under standard laboratory growth conditions, as suggested previously (Shet, Fisher et
al. 1997). As shown, the R597M/W677A reductase mutant, which is able to utilize
NADH in addition to NADPH, roughly doubled the number of revertants compared with
wild-type. To further examine this possibility, mechanisms by which bacteria regulate
oxidized and reduced pools of NADPH and NADH were studied, with the purpose of
developing ways to modulate levels of reduced nucleotides in bacteria in vivo.

By

artificially raising or lowering the concentration of reduced NADPH or NADH, the
question of rate-limitations due to P450 reductase could be studied by further Ames
tests.
Living organisms, including bacteria, require reducing equivalents for respiration
and subsequent production of ATP. These catabolic reducing equivalents are provided
primarily by NADH (and FADH2). Cells also require reducing power for biosynthetic
reactions. Electrons for these anabolic reactions are supplied by NADPH. Bacteria, as
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with other organisms, have control mechanisms which maintain proper redox balance
between oxidized and reduced NADPH and NADH pools. In Salmonella typhimurium,
redox status is maintained by regulation of input of carbohydrates into glycolysis, which
ultimately generates NADH, and the pentose phosphate and Entner-Doudoroff
pathways which generate NADPH.
The primary source of the hydride for NADPH in mammals comes from the
pentose phosphate pathway, also known as the hexose monophosphate shunt. In this
process, glucose-6-phosphate is converted to ribulose 5-phosphate, producing two
NADPH for each molecule converted.

Ribulose-5-phosphate is then converted to

pyruvate and enters the glycolytic (NADH) pathway. While believed to be an important
pathway in E. coli, the pentose phosphate pathway probably supplies less than 50% of
NADPH needs (Csonka and Fraenkel 1977); Orthner and Pizer similarly found that the
pentose phosphate pathway is a major user of glucose (10 - 30%) in E. coli (Orthner
and Pizer 1974). While roughly half of necessary NADPH is produced via the pentose
phosphate pathway, E. coli contain a transhydrogenase capable of transferring
electrons directly from NADH to NADPH which makes a minor contribution to NADPH
levels; the remainder of NADPH is produced through an unidentified pathway (Csonka
and Fraenkel 1977).

The Entner-Doudoroff pathway is present in Salmonella

typhimurium, as well as E. coli, and is a second pathway from glucose to pyruvate
during glycolysis that does not generate fructose-6-phosphate, but instead produces 2keto-3-deoxy-6-phosphogluconate (KDPG) (Peekhaus and Conway 1998). The EntnerDoudoroff pathway shares its first two steps, oxidation of glucose to gluconate and
phosphorylation to 6-phosphogluconate, with the pentose phosphate pathway in
bacteria in a process that produces NADPH and is believed to provide an advantage
during growth in gluconate-rich environments. Inhibition or upregulation of one of these
three pathways might provide a suitable mechanism by which the ratio of reduced
NADPH to NADH could be altered in bacterial cells.
As my data (Fig. 6.3) suggested that the availability of reduced NADPH might be
limiting to the wild-type P450 reductase/P450 2E1 system in Salmonella typhimurium
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under standard laboratory conditions when grown on glucose, means by which the
oxidized versus reduced NADPH and NADH ratios could be modulated in vivo would be
valuable tools to evaluate the significance of such a limitation. The pentose phosphate
pathway, Entner-Doudoroff pathway, and the NADPH/NADH transhydrogenase are
contributors to the NADPH pool in Salmonella typhimurium. 6-Amino-nicotinamide is a
known inhibitor of NAD(P)H dependent enzymes, including what appears to be a
pseudo-specific block of the oxidative steps of the hexose monophosphate shunt in
mammals (Kohler, Barrach et al. 1970).

Though this compound would inhibit the

pentose phosphate pathway and would thereby lower NADPH levels, it would also be
likely to inhibit all nicotinamide coenzyme utilizing enzymes, including the mutant
proteins being evaluated, as well as those enzymes necessary for production of the
nucleotides themselves, and was therefore not used. KDPG, mentioned above as an
intermediate of the Entner-Doudoroff pathway, is a bacteriostatic metabolite that can
inhibit the pentose phosphate pathway at the 6-phosphogluconate dehydrogenase step
(Fuhrman, Wanken et al. 1998; Peekhaus and Conway 1998) and would also
presumably lower NADPH levels. This compound, however, is not readily available
commercially. Finally, it was noted that transhydrogenase activity was low in complex
media, but high on glucose media (Houghton, Fisher et al. 1976). Gerolimatos and
Hanson reported that the inhibitor in complex media was likely to be the amino acid
leucine, which is able to inhibit the transhydrogenase reaction by up to 80%
(Gerolimatos and Hanson 1978). Leucine is readily available and can be easily added
to culture media. Inhibition of transhydrogenase activity might be expected to lower
NADPH levels by inhibiting its synthesis from NADH during exponential growth. On the
other hand, the use of gluconate in place of glucose as the primary carbohydrate source
might be expected to increase the NADPH concentration by stimulating the pentose
phosphate shunt below the rate limiting step of the pentose phosphate pathway (Fig.
6.5).

In the following experiments, gluconate was added to stimulate the Entner-

Doudoroff/pentose phosphate pathways (Pathways B & C). Leucine was added as an
inhibitor of transhydrogenase (Pathway D).
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FIGURE 6.5 Major pathways of production of NADP(H) reduction in Escherichia
coli and Salmonella typhimurium (Csonka and Fraenkel 1977; Gerolimatos and
Hanson 1978; Peekhaus and Conway 1998).

Experimental Design
Ames tests were carried out as described above (Cooper and Porter 2000). The
activation of dimethylnitrosamine in Salmonella typhimurium strain YG7108 was carried
out with pIN3ER plasmids expressing human cytochrome P450 2E1 and either wild-type
cytochrome P450 reductase or the R597M/W677A protein. Single colonies obtained
from electroporation of pIN3ER and mutant plasmid were used to inoculate overnight
cultures in LB media containing 100 µg/mL ampicillin and IPTG-mediated induction of
protein

expression.

Cells

were

mixed
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with

increasing

concentrations

of

dimethylnitrosamine in top agar and plated onto histidine-deficient Vogel-Bonner plates.
Vogel-Bonner plates contained 1% glucose, 1% gluconate, or 1% glucose with 2 mM
leucine. After incubation for 48 hours at 37°C, visible colonies were counted.
Results of Reduced Nucleotide Pool Manipulation
Ames assays were designed to analyze the effects of additions or changes to the
culture media on mutagen activation by cells containing the mutant reductases. These
culture media changes were intended to alter NADH/NADPH cofactor ratios in the cells.
Gluconate was expected to increase NADPH levels relative to cells grown in glucose,
whereas leucine was expected to decrease NADPH levels by blocking the
transhydrogenase reaction. Media favoring an increase in NADPH over NADH should
favor the wild-type reductase.

Conversely, media designed to increase the

NADH/NADPH ratio should favor the R597M/W677A protein versus wild-type, although
my data with the in vitro experiments suggests that the R597M/W677A mutant should
be rather insensitive to variation in nucleotide levels, assuming they remain at roughly
the same total concentration [NADPH+NADH], because this mutant is able to utilize
both cofactors at roughly the same efficiency. Consistent with expectations, with wildtype reductase gluconate slightly increased mutagenicity of DMN, whereas the addition
of leucine to the medium slightly decreased mutagenicity (Fig. 6.6).

However, the

extent of the increase or decrease in mutagenicity was very small and not statistically
significant, as indicated by the overlapping error bars. These results indicate that the
effects of these media modifications on cofactor levels are likely to be small and easily
compensated in the cells.
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FIGURE 6.6 Comparison of wild-type reductase activity in Ames assays cultured
on an array of substrates
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Unexpectedly, cells containing the R597M/W677A reductase mutant maintained
a higher rate of mutagen activation in the presence of gluconate, despite the
expectation that increased NADPH levels would not favor this enzyme. Indeed, DMN
activation in gluconate media was greater than that obtained in glucose media. These
results suggest that gluconate may simply increase reduced cofactor levels available to
the enzyme, and thereby increase overall activity. DMN activation in the presence of
leucine was essentially unchanged from that obtained in glucose media, arguing that
preventing NADPH generation by the transhydrogenase pathway does not impair the
activity of the R597M/W677A reductase mutant (Fig. 6.7). This would further suggest
that the elevated activation of DMN in these cells, relative to cells containing wild-type
reductase, can be attributed to the greater ability of the R597M/W677A reductase to use
the more abundant NADH cofactor. It should be noted, however, that cofactor
levels/ratios were not measured in these cells.
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FIGURE 6.7 Comparison of R597M/W677A reductase activity in Ames assays
cultured on an array of substrates
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Western blotting of P450 reductase shows qualitatively that the wild-type
reductase is expressed at a slightly higher level than the R597M/W677A protein (Fig.
6.8); sodium dodecyl sulfate-polyacrylamide gel electrophoresis shows equal protein
loading. As all recombinant Ames assays show revertants with the RM/WA protein at a
level roughly double that seen with the wild-type enzyme, this increase in DMN
activation with the R597M/W677A reductase cannot be attributed to higher expression
levels of this mutant protein, but rather must be an intrinsic characteristic of this protein.
This is even more surprising given the generally lower activity of this protein when
purified and assayed in vitro, as noted in the earlier studies (Chapters 3 and 5).
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FIGURE 6.8 Sodium dodecyl sulfate – polyacrylamide gel electrophoresis (Lanes
1 & 2) and Western blot (Lanes 3 & 4) of YG7108 Salmonella typhimurium tester
strains expressing reductases proteins. Lane 1 & 3, wild-type reductase; 2 & 4,
R597M/W677A.
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Cytochrome c Assays with Ames Test Salmonella typhimurium Cell Lysates
In agreement with this blot data, cytochrome c reductase activities were
measured with whole cell lysates of YG7108 Salmonella tester cells containing wild-type
or the R597M/W677A reductase and indicate lower activity with the R597M/W677A
reductase than with wild-type (Fig. 6.9). Assays were carried out in 100 mM Tris (pH
8.0), 0.75 mM ionic strength with KCl, 30 µM cytochrome c and 45 µg of total whole cell
lysate protein. Reactions were started by addition of 1 mM nucleotide or a combination
of 1mM for both nucleotides, and were carried out for 60 seconds and were monitored
on a Hewlett Packard 8453 diode array spectrophotometer.

The total reduction of

cytochrome c was monitored at 550 nm using a millimolar extinction coefficient of 21.1
mM-1 for one minute at room temperature.
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As with the blotting data (Fig. 6.8), the lower cytochrome c reductase activity of
the R597M/W677A reductase mutant relative to wild-type reductase in vitro is in marked
contrast to the mutagenicity data obtained in vivo. Although various explanations are
possible, one possibility consistent with all available data is that NADH is significantly
more abundant than NADPH in bacterial cells, and thus the R597M/W677A reductase,
with a 2-fold greater kcat and 500-fold greater catalytic efficiency with NADH than the
wild-type enzyme, has significantly greater activity in this in vivo setting.
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CHAPTER SEVEN
CONCLUSIONS
Nucleotide-specificity of P450 Reductase
Cytochrome P450 reductase has a 45,000-fold preference for NADPH over
NADH, although the two cofactors differ only in the presence of a 2'-phosphate group on
the adenine-ribose of NADPH.

The three-dimensional structure of P450 reductase

revealed three amino acids that interact with this phosphate: serine 596, arginine 597,
and lysine 602 (Wang, Roberts et al. 1997) and it is assumed that these amino acids
dictate the specificity for NADPH. Consistent with this prediction, Sem and Kasper
(Sem and Kasper 1993) showed that substitution of a methionine for the positively
charged arginine at position 597 produces a reductase with impaired ability to
differentiate between the two cofactors. The studies presented here support this role for
arginine 597, and demonstrate that substitution of lysine 602 leads to a further loss in
specificity for NADPH. Of the four amino acids examined in this study, these two have
the greatest influence on NADPH specificity: when combined these substitutions
increase the Km for NADPH by 2,400-fold. The effect of these two substitutions on the
Km for NADH was less predictable:

although both decreased the Km individually

(R597M 2-fold and K602W 5-fold), when combined the decrease was only about 1.5fold.

Moreover, the K602W mutation greatly decreased turnover with NADH.

It is

unclear why the substitution of tryptophan at this position should have such a
detrimental effect on NADH-dependent activity, as sequence alignments suggest that a
tryptophan is found at this position in NADH-specific enzymes (Fig. 1.10). Given the
ambiguity in the alignments of the NADH-specific proteins in this region, it is possible
that substitutions other than tryptophan at this position might more readily
accommodate NADH binding and turnover.
Work by Scrutton and Perham (Scrutton, Berry et al. 1990; Bocanegra, Scrutton
et al. 1993; Mittl, Berry et al. 1993) on the conversion of glutathione reductase to an
NADH-specific enzyme suggested that an acidic residue opposite the adenine-ribose
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hydroxyls should enhance the binding of NADH. This position is occupied by serine 596
in P450 reductase (Fig. 1.10). Consistent with this hypothesis, several NADH-specific
reductases, including cytochrome b5 reductase, contain an aspartate at this position.
We generated the corresponding mutant in P450 reductase (S596D) but the resulting
protein exhibited poor turnover with both NADH and NADPH.

Although it was

anticipated that a negatively charged amino acid at this position would strongly oppose
NADPH binding by repelling the 2'-phosphate (and indeed, the Km for NADPH increased
by over 20,000-fold), the marked decrease in kcat with NADH was not expected.
Although the Km for NADH decreased by greater than half, it was not enough to
overcome the 90% decrease in catalytic activity.

The incorporation of additional

mutations in the 2'-phosphate-binding site (R597M, K602W) or the W677A mutation did
not restore activity with either cofactor, suggesting that the S596D substitution disrupted
the structure of the cofactor-binding pocket.

Thus, like the K602W mutation, the

substitution of an “NADH-specific” amino acid at this position had the expected effect on
activity with NADPH but did not enhance activity with NADH.
Gutierrez et al. (Gutierrez, Doehr et al. 2000) reported that, in contrast to native
P450 reductase, a stable enzyme-NADP+ complex could be formed with a reductase in
which histidine is substituted for tryptophan 677. This tryptophan lies directly opposite
the FAD isoalloxazine ring and is suggested to serve as a gating mechanism for
cofactor binding. In support of this idea, movement of the tryptophan is seen during
NADP(H) binding and release (Gutierrez, Paine et al. 2002). Loss or substitution of this
tryptophan should enhance the binding of both NADH and NADPH, and indeed a
remarkable increase in turnover with NADH is seen in W677 mutants (Dohr, Paine et al.
2001).

However, turnover with NADPH is greatly decreased, apparently due to

formation of this stable enzyme-NADP+ complex. Second-site mutations that decrease
the affinity of the enzyme for NADP(H) would be expected to decrease the stability of
the enzyme-NADP+ complex and decrease the inhibition by NADP+. Consistent with
this expectation, the R597M/W677A and R597M/K602W/W677A proteins were inhibited
only at high NADP+ concentrations, and retained good activity in the presence of both
cofactors in an in vitro P450 assay.
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Wild-type P450 reductase is evolutionarily designed to exclusively bind NADPH.
Gluconate was added as a substrate to increase the NADPH/NADH ratio in Salmonella
typhimurium during Ames tests. Wild-type reductase showed higher activation of DMN
on gluconate in agreement with an increase in reduced NADPH levels versus glucose.
The amino acid leucine was added to decrease the ratio of NADPH to NADH through
inhibition of the transhydrogenase.

Consistent with this hypothesis, wild-type P450

reductase showed reduced ability to activate DMN in the presence of leucine. The
R597M/W677A protein, which showed strong NADH-dependent activity in vitro,
produced a more sensitive Ames test, presumably due to a greater ability to utilize
NADH for cytochrome P450 2E1-mediated activation of dimethylnitrosamine. However,
the R597M/W677A protein also showed high activity with gluconate, a media designed
to increase the NADPH/NADH ratio. Though unexpected, these data do not exclude
the possibility that NADH utilization provides the R597M/W677A proteins superior
activity in vivo.
Future Studies with P450 Reductase Proteins
Although I have identified mutations that enhanced the ability of P450 reductase
to use NADH in the presence of NADPH, I did not create a reductase that is more
efficient with NADH than NADPH. Even with the best mutants (R597M/W677A and
R597M/K602W/W677A), the catalytic efficiency values (kcat/Km) for NADPH and NADH
were, at best, equivalent. Thus it remains unclear how to engineer a P450 reductase to
preferentially use NADH.

Notably, a number of NADH-utilizing enzymes exhibit a

preference for NADH over NADPH; for example, turnover with NADPH in NADHdependent E. coli dihydrolipoamide dehydrogenase is undetectable (Bocanegra,
Scrutton et al. 1993). Sequence comparisons of the cofactor-binding region of this
protein to P450 reductase do not reveal obvious differences that might explain the
greater selectivity of the dehydrogenase for NADH. Further biochemical and perhaps
biophysical studies on P450 reductase will be needed to identify the additional changes
needed to enhance selectivity for NADH. “Second-generation” mutants, based on the
results of present studies, might be more effective. For example, substitution of aspartic
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or glutamic acid for arginine 597, rather than methionine as was done in the present
studies, might promote binding of NADH; the uncharged methionine residue reduced
the catalytic efficiency with NADPH by 100-fold, but only increased the efficiency with
NADH by 2-fold. The alignment data with NADH-specific enzymes suggests that an
acidic amino acid in this segment is necessary for efficient NADH binding, but the exact
location is unclear. In my studies, an acidic amino acid was incorporated at the position
immediately preceding Arg597, but this substitution (Ser596Asp) yielded a protein with
little activity with either nucleotide cofactor.

Perhaps the location in 3-dimensional

space of this acidic residue is critical to function.

A second possible “second-

generation” mutant, replacement of lysine 602 with alanine, rather than tryptophan as
chosen from sequence alignment, might decrease NADPH-binding without negatively
influencing interactions with NADH due to a bulky hydrophobic side-chain. Substitution
of an acidic side-chain at the 602 position might also improve binding of NADH by
providing an additional hydrogen bonding residue for the adenine hydroxyl of NADH.
Site-directed mutagenesis, while a hypothesis-driven technique, limits the
number of substitutions that may be analyzed.

A technique, such as random

mutagenesis or gene shuffling, which maximizes the number and types of enzyme
alterations, might produce a P450 reductase that shows a more profound switch in
cofactor specificity than those mutants presented here. Random mutagenesis has been
used to generate P450 enzymes with altered substrate specificity.

In studies by

Guengerich and colleagues, indole was shown to be metabolized by P450 1A2 and
randomly generated 1A2 mutants coexpressed with P450 reductase in E. coli, to a
variety of pigment compounds, including indigo (Nakamura, Martin et al. 2001). Such a
screening technique might provide a way to analyze large numbers of randomly
generated P450 reductase mutants by their ability to stimulate the P450 1A2-mediated
conversion of indole to indigo.

Perhaps the Ames test might provide an adequate

screen for sorting the large number of enzymes produced. One limitation of this screen
is that it might be difficult to distinguish between NADH-specific and reversion to wildtype NADPH activity. Additionally, an Ames assay screen would be expensive due to
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the large numbers of plates that would be needed to analyze the many mutant proteins
generated.
The studies reported here do indicate that it is possible to engineer P450
reductase for use in vivo by rational design and subsequent evaluation of enzymes in
vitro. In addition to providing a valuable tool for understanding the determinants of
nucleotide cofactor specificity, these mutants might also lend themselves to creation of
bioremediation with increased enzymatic activity, as well as cost-effective reconstitution
of enzyme systems that do not require the use of expensive reducing equivalents from
NADPH.
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